SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma

Jin, Guang‐Zhi; Yu, Wenlong; Dong, Hui; Zhou, Weiping; Gu, Yijin; Yu, Hao; Yu, Hua; Lu, Xin; Xian, Zhi‐Hong; Liu, Yinkun; Wu, Mengchao

doi:10.1016/j.jhep.2013.04.028

Cited by 64 publications

(42 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD34 had a well sensitivity in the differential diagnosis between HGDNs and WD-sHCC [17]. In order to improve the sensitivity of LIFR in detection of sHCC, CD34 was selected as a combined biomarker in our study.…”

Section: Resultsmentioning

confidence: 99%

“…CD34 had a high sensitivity for distinguishing WD-sHCC from HGDNs, however its positive staining may also occur in some confusing cases of HGDNs [10]. In the last decade, several immunohistochemistry markers such as clathrin heavy chain, EZH2, SUOX, ACY1, SQSTM1 and AKR1B10 were used single or in panel to distinguish WD-sHCC from HGDN [17, 22–24]. Somatic TERT promoter mutation was also identified as a new biomarker for transformation of premalignant lesions into HCC [21].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Leukemia inhibitory factor receptor is a novel immunomarker in distinction of well-differentiated HCC from dysplastic nodules

et al. 2015

View full text Add to dashboard Cite

Differential diagnosis of well-differentiated hepatocellular carcinoma (WD-HCC) and high-grade dysplastic nodules (HGDNs) represents a challenge for pathologists. Several immunohistochemistry markers have been identified to distinguish hepatocellular carcinoma (HCC) from HGDNs. However, sensitivity or specificity of the individual marker is still limited. In this study, we analyzed dynamic alteration of leukemia inhibitory factor receptor (LIFR) and CD34 during hepatocarcinogenesis from dysplastic nodules to small HCC. The diagnostic performance of LIFR and CD34 combination in WD-HCC and HGDNs was investigated by logistic regression models and validated in an independent validation cohort. LIFR was decreased and CD34 was increased along with stepwise progression of hepatocarcinogenesis from low-grade dysplastic nodules (LGDNs) to small HCC. The sensitivity and specificity of the LIFR and CD34 combination for WD-HCC detection were 93.5% and 90.5%, respectively. In addition, colony formation assay was used to explore the role of LIFR in tumorigenesis. Silencing of LIFR could significantly promote colony formation of HCC cells, whereas ectopic overexpression of LIFR resulted in impaired ability of colony formation of HCC cells. These findings indicate that LIFR and CD34 combination may be used as an available differential diagnostic model for WD-HCC from HGDNs in clinical practice.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Leukemia inhibitory factor receptor is a novel immunomarker in distinction of well-differentiated HCC from dysplastic nodules

et al. 2015

View full text Add to dashboard Cite

show abstract

“…However, at present, there is still lack of sensitive and special molecular markers available for the differential diagnosis between dysplastic nodules and early HCC, although there are increasing biomarker panels waiting for multi-centric validations (Table 1). Comparatively, there are a few proposed immunohistochemical markers, such as glypican-3 (GPC-3), heat-shock protein-70 (HSP-70), glutamine synthetase (GS), CD34 and sulfite oxidase (SUOX), which might help to distinguish above two entities [49,50].…”

Section: Molecular Evaluation Of Precancerous Lesionsmentioning

confidence: 99%

New insights into molecular diagnostic pathology of primary liver cancer: Advances and challenges

Wang

2015

Cancer Letters

Self Cite

View full text Add to dashboard Cite

“…Hepatocellular carcinoma (HCC) is the sixth most common solid neoplasm and the leading cause of cancer-related death in the world with 55% occurring in China [1-3]. According to a recent report from the International Agency for Research on Cancer, HCC has become the second most common cause of cancer-related death and accounts for 9.1% (0.8 million) of the global cancer-related deaths in 2012 [4].…”

Section: Introductionmentioning

confidence: 99%

Interferon-stimulated Gene 15 (ISG15) is a trigger for tumorigenesis and metastasis of hepatocellular carcinoma

Zhang

et al. 2014

Oncotarget

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide with poor prognosis. IFN-stimulated genes 15 (ISG15) is an ubiquitin-like molecule that is strongly upregulated by type I interferons as a primary response to diverse microbial and cellular stress stimuli. However, the role of ISG15 in HCC remains unclear. In this study, we investigated the function of ISG15 during HCC progression and related mechanism using clinicopathological data, cell line and xenograft model. Our results indicated that ISG15 is highly expressed in HCC tissues and multiple HCC cell lines. ISG15 expression is significantly associated with the differentiation grade, metastatic of tumor and survival of HCC patients. However, the expression of ISG15 is not affected by HBV infection. ISG15 promotes the proliferation and migration of hepatocarcinoma cells through maintaining Survivin protein stabilization via sequestering XIAP from interacting with Survivin. Knowing down ISG15 with SiRNA inhibited the xenografted tumor growth and prolonged the lifespan of tumor-bearing mice. All these results support that ISG15 high expression is an intrinsic feature for HCC and a trigger for tumorigenesis and metastasis. ISG15 may be a prognostic biomarker and the inhibition of ISG15 could provide a therapeutic advantage for HCC patients over-expressing ISG15.

show abstract

SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma

Cited by 64 publications

References 26 publications

Leukemia inhibitory factor receptor is a novel immunomarker in distinction of well-differentiated HCC from dysplastic nodules

Leukemia inhibitory factor receptor is a novel immunomarker in distinction of well-differentiated HCC from dysplastic nodules

New insights into molecular diagnostic pathology of primary liver cancer: Advances and challenges

Interferon-stimulated Gene 15 (ISG15) is a trigger for tumorigenesis and metastasis of hepatocellular carcinoma

Contact Info

Product

Resources

About